Green LifeScience Co

Green LifeScience Co EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Green LifeScience Co (114450.KQ) as of Oct 27, 2026 is 257.87. In the previous year, EV/EBIT (Enterprise Value to EBIT) was 139.77 — a change of 84.49% (higher).

EV/EBIT

257.87

YoY

84.49%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Green LifeScience Co is 2025 257.87 . EV/EBIT (Enterprise Value to EBIT) of Green LifeScience Co was 2024 139.77 . It decreases by 84.49% higher compared to the previous year.

The Green LifeScience Co EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2018
-26.99 KRW
Jan 1, 2019
89.12 KRW
Jan 1, 2020
-27.60 KRW
Jan 1, 2021
-11.33 KRW
Jan 1, 2022
-13.31 KRW
Jan 1, 2023
-3.15 KRW
Jan 1, 2024
139.77 KRW
Jan 1, 2025
257.87 KRW
The Green LifeScience Co EV/EBIT history
YEAREV/EBITYoY
257.87+84.49%
139.77-4,540.78%
-3.15-76.35%
-13.31+17.44%
-11.33-58.93%
-27.60-130.96%
89.12-430.25%
-26.99-223.35%
21.88+109.01%
10.47+10.23%
9.50-132.99%
-28.78+49.37%
-19.27-232.90%
14.50+49.18%
9.72-25.29%
13.01+182.21%
4.61—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Green LifeScience Co Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Green LifeScience Co's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Green LifeScience Co's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Green LifeScience Co's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Green LifeScience Co grows earnings faster than its peers.

Green LifeScience Co Stock analysis

What does Green LifeScience Co do? Green LifeScience Co Ltd produces and sells pharmaceutical and agricultural raw materials and intermediates, including AMZ for crop protection, TAZD as a herbicide intermediate, D003M and T003M for artificial marble additives, and PM04 as a pharmaceutical intermediate. The company distributes its products domestically and to international markets such as Japan, the United States, and Europe, where customers purchase these materials for agricultural and pharmaceutical applications. The firm also offers antibiotics as part of its product portfolio, targeting both domestic and overseas buyers seeking specialized chemical compounds. Green LifeScience Co Ltd generates revenue through the sale of its chemical products to customers in the agricultural and pharmaceutical sectors, with key markets including Japan, the United States, and European countries. The company’s product line caters to the needs of manufacturers requiring raw materials for crop protection, herbicides, and pharmaceutical production. Its domestic and international distribution channels support consistent sales across these segments, leveraging established relationships with buyers in the chemical supply chain. The company's offerings include specific chemical compounds like AMZ, TAZD, D003M, T003M, and PM04, which are sold to customers who integrate them into larger production processes. These products are used in the creation of crop protection materials, herbicides, artificial marble, and pharmaceuticals, serving both local and global markets. Antibiotics are also part of the sales mix, contributing to the firm’s revenue from chemical intermediates and raw materials. Green LifeScience Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Green LifeScience Co stock

EV/EBIT (Enterprise Value to EBIT) of Green LifeScience Co is 257.87 in 2025.

EV/EBIT (Enterprise Value to EBIT) of Green LifeScience Co changed from 139.77 to 257.87, representing a 84.49% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Green LifeScience Co since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Green LifeScience Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Green LifeScience Co

All Key Metrics — Green LifeScience Co